From the perspective of the development of global medical device market，acquiring technology，product line，patent，channel and market is still the key method of merger and acquisition （M&A） strategy. The drastic changes in the global medical device regulations will reshape the market of medical device in China，and the channels，manufacturing，marketing systems will continue to be integrated. With the influence of national healthcare reform policy and implementation of “Two-invoice system”，consolidation speed in medical device industry has been accelerated，with the industry maturing gradually，the investment tending to be rational，the transaction increasing in biotechnology and medical device field，the average investment amount soaring，and the investment concentration augmenting. This is a price-based value chain reconstruction，and it is also a great benefit game in pharmaceutical circulation chain under institutional reform. At present，invigorating large enterprise while phasing out small ones is the general regulation policy in medical device industry，in whichspecial rectification is carried out in distribution field，“small，scattered，disordered” companies are facing great policy pressure，and the small& medium-sized commercial enterprises without competition and market covering ability will be eliminated，thus ushering in the partner mechanism. This profound reform featuring equity allocation，equity incentive，public financing，equity merger will promote the rapid development of medical device industry.